Loading search results

Conditions

Keywords

recurrent cutaneous T-cell non-Hodgkin lymphomastage II cutaneous T-cell non-Hodgkin lymphomastage III cutaneous T-cell non-Hodgkin lymphomastage IV cutaneous T-cell non-Hodgkin lymphomarecurrent mycosis fungoides/Sezary syndromestage II mycosis fungoides/Sezary syndromestage III mycosis fungoides/Sezary syndromestage IV mycosis fungoides/Sezary syndrome

Eligibility Criteria

Age18 Years+

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

DISEASE CHARACTERISTICS: * Histologically confirmed cutaneous T-cell lymphoma * Refractory to prior treatment * Stage IIA, IIB, III, IVA, or IVB disease * Measurable disease PATIENT CHARACTERISTICS: Age * 18 and over Performance status * ECOG 0-2 Life expectancy * At least 3 months Hematopoietic * Not specified Hepatic * AST and/or ALT ≤ 3 times upper limit of normal * Hepatitis B and/or hepatitis C negative Renal * Creatinine clearance ≥ 40 mL/min Immunologic * Human T-cell lymphotrophic virus type I (HTLV-I) negative * HIV negative * No active serious infection not controlled by antibiotics Other * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception * No known impaired absorption of the gastrointestinal tract * No other illness that would preclude study participation PRIOR CONCURRENT THERAPY: Biologic therapy * Not specified Chemotherapy * More than 21 days since prior chemotherapy and recovered Endocrine therapy * Concurrent topical corticosteroids allowed provided patient remains on a stable dose Radiotherapy * No concurrent radiotherapy Surgery * Not specified Other * More than 30 days since prior investigational agents and recovered * No concurrent tanning bed use * No other concurrent therapy for cutaneous T-cell lymphoma

Study Sites (10)

Lurleen Wallace Comprehensive Cancer at University of Alabama-Birmingham

Birmingham, Alabama, 35294, United States

Burke Pharmaceutical Research

Hot Springs, Arkansas, 71913, United States

Stanford Comprehensive Cancer Center - Stanford

Stanford, California, 94305, United States

University of Colorado Cancer Center at UC Health Sciences Center

Aurora, Colorado, 80045, United States

Yale Cancer Center

New Haven, Connecticut, 06520-8028, United States

Cancer and Blood Disease Center

Lecanto, Florida, 34461, United States

Dana-Farber/Brigham and Women's Cancer Center

MeSH Terms

Conditions

LymphomaLymphoma, T-Cell, CutaneousMycosis FungoidesSezary Syndrome

Condition Hierarchy (Ancestors)

Neoplasms by Histologic TypeNeoplasmsLymphoproliferative DisordersLymphatic DiseasesHemic and Lymphatic DiseasesImmunoproliferative DisordersImmune System DiseasesLymphoma, T-CellLymphoma, Non-Hodgkin

Forodesine (BCX-1777) in Treating Patients With Refractory Stage IIA, Stage IIB, Stage III, Stage IVA, or Stage IVB Cutaneous T-Cell Lymphoma

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Interventions

Eligibility Criteria

Sponsors & Collaborators

Study Sites (10)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Design

Study Record Dates

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Interventions

Eligibility Criteria

Sponsors & Collaborators

Study Sites (10)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Design

Study Record Dates

Source record

Locations